Download PDF
Thromb Haemost 2021; 121(03): 366-382
DOI: 10.1055/s-0040-1716752
Stroke, Systemic or Venous Thromboembolism

Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis

Vasyl Katerenchuk 
1   Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
,
Gonçalo S. Duarte 
2   Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
3   Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
4   Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa (CAML), Lisboa, Portugal
,
Gonçalo Martins e Pereira
1   Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
,
Ricardo M. Fernandes
2   Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
3   Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
5   Serviço de Pediatria, Hospital de Santa Maria - Centro Hospitalar Universitário de Lisboa Norte (CHLN), Centro Académico de Medicina de Lisboa, (CAML) Lisboa, Portugal
,
Joaquim J. Ferreira
2   Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
3   Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
6   CNS - Campus Neurológico Sénior, Torres Vedras, Portugal
,
Fausto J. Pinto
7   Serviço de Cardiologia, Hospital de Santa Maria-CHLN, CAML, Centro Cardiovascular da Universidade de Lisboa - CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
,
João Costa
2   Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
3   Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
4   Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa (CAML), Lisboa, Portugal
,
Daniel Caldeira 
2   Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
3   Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
7   Serviço de Cardiologia, Hospital de Santa Maria-CHLN, CAML, Centro Cardiovascular da Universidade de Lisboa - CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective To undertake a systematic review and meta-analysis to assess the satisfaction of patients receiving nonvitamin K anticoagulants (NOACs), compared with vitamin K antagonists (VKAs).

Methods We searched CENTRAL, MEDLINE, Embase, and Clinicaltrials.gov for randomized controlled trials (RCTs) and observational studies. Two reviewers screened, extracted, and appraised data independently. We pooled data using a random-effects model. Outcome included treatment satisfaction, which was assessed by scores of Duke Anticoagulation Satisfaction Scale (DASS), Anticlot Treatment Scale (ACTS), Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2), or Treatment Satisfaction Questionnaire for Medication version II (TSQM-VII) and their domains reported with 95% confidence intervals (95% CIs). We followed MOOSE and PRISMA guidelines.

Results We included four RCTs and 16 observational studies, enrolling 18,684 participants overall. Compared with VKAs, treatment with NOACs improved the ACTS Burdens score by 4.21 points (95% CI: 2.99–5.43, I 2 = 95%, combined n = 6,180), and ACTS Benefits by 0.49 points (95% CI: 0.18–0.81, I 2 = 85%, combined n = 6,171). Switching from VKAs to NOACs improved the ACTS Burdens score by 5.33 points (95% CI: 3.53–7.14, combined n = 3,097). Compared with VKAs, treatment with NOACs improved the TSQM-VII Global Satisfaction score by 6.86 points (95% CI: 3.00–10.73, combined n = 5,535).

Conclusion In patients with nonvalvular atrial fibrillation or venous thromboembolism, NOAC treatment is associated with greater satisfaction compared with VKAs. The switch from VKAs to NOACs was associated with improved patients' satisfaction. These effects were largely due to a lower degree of treatment burden with NOAC treatment.

Keywords

nonvitamin K anticoagulants - satisfaction - anticoagulation - vitamin K antagonists

Authors' Contributions

D.C., G.M.P., and V.K. conceived the idea for the protocol and made the main contribution to planning and preparation of timelines for its completion. V.K. and G.S.D. planned the data extraction and statistical analysis, as well as risk of bias, quality of evidence, and completeness of reporting assessments. V.K. designed the tables and wrote the first draft of the manuscript, which was then reviewed and amended by D.C., G.M.P., G.S.D., R.M.F., J.J.F., F.J.P., and J.C. All authors then approved the final written manuscript. D.C. is the guarantor for the work.


Supplementary Material



Publication History

Received: 04 June 2020

Accepted: 08 August 2020

Article published online:
07 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Letter to this article:

Patient Satisfaction: A Key Component in Increasing Treatment Adherence and PersistenceThromb Haemost 2021; 121(03): 255-257
DOI: 10.1055/s-0040-1718734

 

  • References

  • 1 Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014; 8: 789-798
    CrossrefPubMedSearch in Google Scholar
  • 2 Cohen AT, Hamilton M, Mitchell SA. et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 2015; 10 (12) e0144856
    CrossrefPubMedSearch in Google Scholar
  • 3 Schulman S, Singer D, Ageno W, Casella IB, Desch M, Goldhaber SZ. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost 2017; 117 (07) 1317-1325
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Banerjee A, Benedetto V, Gichuru P. et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart 2020; 106 (02) 119-126
    CrossrefPubMedSearch in Google Scholar
  • 5 Alegret JM, Viñolas X, Arias MA. et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci 2014; 11 (07) 680-684
    CrossrefPubMedSearch in Google Scholar
  • 6 Caldeira D, Cruz I, Morgado G. et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014; 7 (891) 891
    CrossrefPubMedSearch in Google Scholar
  • 7 Barrios V, Escobar C, Prieto L. et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA Study. Rev Esp Cardiol (Engl Ed) 2015; 68 (09) 769-776
    CrossrefPubMedSearch in Google Scholar
  • 8 Erkens PMG, ten Cate H, Büller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012; 7 (09) e42269
    CrossrefPubMedSearch in Google Scholar
  • 9 Lip GYH, Andreotti F, Fauchier L. et al. Document reviewers. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13 (05) 723-746
    CrossrefPubMedSearch in Google Scholar
  • 10 Caldeira D, Rodrigues FB, Barra M. et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 2015; 101 (15) 1204-1211
    CrossrefPubMedSearch in Google Scholar
  • 11 Kirchhof P, Benussi S, Kotecha D. et al. ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedSearch in Google Scholar
  • 12 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019; 140: e125-e151
    CrossrefPubMedSearch in Google Scholar
  • 13 Konstantinides SV, Meyer G, Becattini C. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedSearch in Google Scholar
  • 14 De Caterina R, Brüggenjürgen B, Darius H. et al. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis 2018; 111 (02) 74-84
    CrossrefPubMedSearch in Google Scholar
  • 15 Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8 (Suppl. 01) S9-S24
    CrossrefPubMedSearch in Google Scholar
  • 16 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (05) 487-497
    CrossrefPubMedSearch in Google Scholar
  • 17 Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014; 133 (04) 550-554
    CrossrefPubMedSearch in Google Scholar
  • 18 Shore S, Carey EP, Turakhia MP. et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014; 167 (06) 810-817
    CrossrefPubMedSearch in Google Scholar
  • 19 Bamber L, Wang MY, Prins MH. et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013; 110 (04) 732-741
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Prins MH, Bamber L, Cano SJ. et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015; 135 (02) 281-288
    CrossrefPubMedSearch in Google Scholar
  • 21 Palacio AM, Kirolos I, Tamariz L. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence 2015; 9: 133-138
    PubMedSearch in Google Scholar
  • 22 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283 (15) 2008-2012
    CrossrefPubMedSearch in Google Scholar
  • 23 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
    CrossrefPubMedSearch in Google Scholar
  • 24 Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 2012; 10: 120
    CrossrefPubMedSearch in Google Scholar
  • 25 Prins MH, Guillemin I, Gilet H. et al. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 2009; 7: 30
    CrossrefPubMedSearch in Google Scholar
  • 26 Prins MH, Marrel A, Carita P. et al. Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the ‘Perception of Anticoagulant Treatment Questionnaire’ (PACT-Q). Health Qual Life Outcomes 2009; 7: 9
    CrossrefPubMedSearch in Google Scholar
  • 27 Samsa G, Matchar DB, Dolor RJ. et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004; 2: 22
    CrossrefPubMedSearch in Google Scholar
  • 28 Duarte GS, Nunes-Ferreira A, Rodrigues FB. et al. Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open 2019; 9 (03) e025232
    CrossrefPubMedSearch in Google Scholar
  • 29 The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0. Higgins JPT, Green S. , eds. 2011. . Available at: https://handbook-5-1.cochrane.org
    Search in Google Scholar
  • 30 Wells GA, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed February 6, 2020
  • 31 Caldeira D, Costa J, Barra M, Pinto FJ, Ferreira JJ. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. Thromb Res 2015; 135 (01) 58-61
    CrossrefPubMedSearch in Google Scholar
  • 32 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21 (11) 1539-1558
    CrossrefPubMedSearch in Google Scholar
  • 33 Okumura Y, Yokoyama K, Matsumoto N. et al. SAKURA AF Registry Investigators. Patient satisfaction with direct oral anticoagulants and warfarin. Int Heart J 2018; 59 (06) 1266-1274
    CrossrefPubMedSearch in Google Scholar
  • 34 Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart 2020; 106 (05) 350-357
    CrossrefPubMedSearch in Google Scholar
  • 35 Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlabum; 1988
    Search in Google Scholar
  • 36 Schünemann H, Brożek J, Guyatt G, Oxman A. , eds. GRADE Handbook: Handbook for Grading the Quality of Evidence and the Strength of Recommendations using the GRADE Approach. 2013 . Available at: https://gdt.gradepro.org/app/handbook/handbook.html . Accessed August 28, 2020
    Search in Google Scholar
  • 37 Heeringa J, van der Kuip DAM, Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27 (08) 949-953
    CrossrefPubMedSearch in Google Scholar
  • 38 Hohnloser SH, Cappato R, Ezekowitz MD. et al. X-VeRT Steering Committee and Investigators. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace 2016; 18 (02) 184-190
    CrossrefPubMedSearch in Google Scholar
  • 39 Goette A, Kwong WJ, Ezekowitz MD. et al. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace 2018; 20 (12) 1936-1943
    CrossrefPubMedSearch in Google Scholar
  • 40 Fareau S, Baumstarck K, Farcet A, Molines C, Auquier P, Retornaz F. Évaluation de la qualité de vie des patients âgés en fibrillation atriale sous anticoagulants au long cours : antivitamine K versus anticoagulants oraux directs. Geriatr Psychol Neuropsychiatr Vieil 2015; 13 (01) 45-54
    PubMedSearch in Google Scholar
  • 41 Benzimra M, Bonnamour B, Duracinsky M. et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence 2018; 12: 79-87
    CrossrefPubMedSearch in Google Scholar
  • 42 Larochelle J, Brais C, Blais L. et al. Patients' perception of newly initiated oral anticoagulant treatment for atrial fibrillation: an observational study. J Gen Intern Med 2018; 33 (08) 1239-1241
    CrossrefPubMedSearch in Google Scholar
  • 43 Keita I, Aubin-Auger I, Lalanne C. et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence 2017; 11: 1625-1634
    Search in Google Scholar
  • 44 Coleman CI, Haas S, Turpie AGG. et al. XANTUS Investigators. Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol 2016; 39 (10) 565-569
    CrossrefPubMedSearch in Google Scholar
  • 45 Koretsune Y, Kumagai K, Uchiyama S. et al. Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study. Curr Med Res Opin 2018; 34 (12) 2157-2164
    CrossrefPubMedSearch in Google Scholar
  • 46 Koretsune Y, Ikeda T, Kozuma K. et al. Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study. Patient Prefer Adherence 2017; 11: 1987-1996
    CrossrefPubMedSearch in Google Scholar
  • 47 Wilke T, Bloempott S, Henry MMS. Treatment burden associated with different anticoagulation strategies of atrial fibrillation patients: an observational study in Germany, Sweden and Switzerland based on the Anti-Clot Treatment Scale. Value Health 2018; 21: S117
    CrossrefPubMedSearch in Google Scholar
  • 48 Stephenson JJ, Shinde MU, Kwong WJ, Fu AC, Tan H, Weintraub WS. Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy. Patient Prefer Adherence 2018; 12: 105-117
    CrossrefPubMedSearch in Google Scholar
  • 49 Geng YP, Lan DH, Liu N. et al. Patient-reported treatment satisfaction with dabigatran versus warfarin in patients with non-valvular atrial fibrillation in China. Thromb Haemost 2018; 118 (10) 1815-1822
    Thieme ConnectPubMedSearch in Google Scholar
  • 50 Cabbar F, Cabbar AT, Coşansu K, Çekirdekçi Eİ. Effects of direct oral anticoagulants on quality of life during periprocedural management for dental extractions. J Oral Maxillofac Surg 2019; 77 (05) 904-911
    CrossrefPubMedSearch in Google Scholar
  • 51 Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur REG. Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract 2004; 5: 15
    CrossrefPubMedSearch in Google Scholar
  • 52 Frykman V, Beerman B, Rydén L, Rosenqvist M. Medical Products Agency, Swedish Society of Cardiology. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001; 22 (20) 1954-1959
    CrossrefPubMedSearch in Google Scholar
  • 53 Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 (3, Suppl): S217-S232
    CrossrefPubMedSearch in Google Scholar
  • 54 Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4: 70
    CrossrefPubMedSearch in Google Scholar
  • 55 Hanon O, Chaussade E, Gueranger P, Gruson E, Bonan S, Gay A. Patient-reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French observational study, the SAFARI study. PLoS One 2016; 11 (12) e0166218
    CrossrefPubMedSearch in Google Scholar
  • 56 Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LR. Adherence to oral anticoagulants in atrial fibrillation: an Australian survey. J Cardiovasc Pharmacol Ther 2018; 23 (04) 337-343
    CrossrefPubMedSearch in Google Scholar
  • 57 Pisters R, de Vos CB, Nieuwlaat R, Crijns HJGM. Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. Semin Thromb Hemost 2009; 35 (06) 554-559
    Thieme ConnectPubMedSearch in Google Scholar
  • 58 Obamiro KO, Chalmers L, Bereznicki LRE. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs 2016; 16 (05) 349-363
    CrossrefPubMedSearch in Google Scholar
  • 59 Caldeira D, Barra M, David C, Costa J, Ferreira JJ, Pinto FJ. The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: systematic review and meta-analysis of observational studies. Rev Port Cardiol 2014; 33 (09) 555-560
    CrossrefPubMedSearch in Google Scholar
  • 60 Caldeira D, Ferreira JJ, Pinto FJ. The era of the novel oral anticoagulants in Portugal. Rev Port Cardiol 2017; 36 (7–8): 577-578
    CrossrefPubMedSearch in Google Scholar
  • 61 Cano S, Mantovani L, Folkerts K. et al. Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. TH Open 2018; 2 (02) e139-e146
    Thieme ConnectPubMedSearch in Google Scholar
  • 62 Suárez Fernández C, Castilla-Guerra L, Hinojosa JC. et al. Satisfaction with oral anticoagulants in patients with atrial fibrillation. Patient Prefer Adherence 2018; 12: 267-274
    CrossrefPubMedSearch in Google Scholar